Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21598427 | 0.98 | NOTUM (0.39) | NOTUMP2RX7PARP1BCHEACHE | |
| SCHEMBL21605256 | 0.89 | GRIA1 (0.38) | P2RX7BCHE | |
| Hydrochloric Acid SCHEMBL21598419 | 0.87 | GRIA1 (0.37) | P2RX7BCHE | |
| Hydrochloric Acid SCHEMBL30147766 | 0.87 | GRIA1 (0.37) | P2RX7BCHE | |
| SCHEMBL20462066 | 0.81 | NOTUM (0.40) | NOTUMP2RX7PARP1PARP10PARP11 | |
| SCHEMBL257377 | 0.78 | GAA (0.45) | NOTUMP2RX7PARP1CRBN | |
| SCHEMBL28227757 | 0.77 | P2RX7 (0.37) | NOTUMP2RX7PARP1PARP10PARP11 | |
| SCHEMBL4665676 | 0.76 | MAPT (0.46) | NOTUMP2RX7PARP1BCHEACHE | |
| SCHEMBL6583559 | 0.75 | NOTUM (0.36) | NOTUMP2RX7PARP1PARP10PARP11 | |
| SCHEMBL27453211 | 0.74 | NOTUM (0.39) | NOTUMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | NOTUM 3635/4885P2RX7 3678/4885PARP1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.